Key points of the international Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas （2023）

Jiasu LI; Hongxin SUN; Zhaoshen LI

doi:10.12449/JCH240307

Volume 40 Issue 3

Mar. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(3): 478-482

PDF( 1026 KB)

Key points of the international Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas （2023）

DOI: 10.12449/JCH240307

Department of Gastroenterology，Digestive Endoscopy Center，Changhai Hospital，Navy Medical University，Shanghai 200433，China

More Information

Corresponding author: SUN Hongxin， sunhongxin_0923@163.com （ORCID： 0009-0005-5936-353X）; LI Zhaoshen， zhs.li@hotmail.com （ORCID： 0009-0008-4935-0462）
Received Date: 2024-01-04
Accepted Date: 2024-01-18
Published Date: 2024-03-20

Abstract

Abstract

Recently， the International Association of Pancreatology published a revised edition of the guidelines for the management of intraductal papillary mucinous neoplasm （IPMN） of the pancreas. The guidelines mainly focus on five topics， i.e.， revision of “high-risk stigmata” and “worrisome features”， surveillance of unresected IPMN， surveillance after resection of IPMN， revision of pathological aspects， and research on molecular markers in cyst fluid， in order to provide the best evidence-based reference for clinical practice. This article makes an excerpt of the key points in the guidelines.
- Pancreatic Intraductal Neoplasms,
- Diagnosis,
- Surveillance,
- Guidelines

FullText(HTML)

References(1)

References

[1]	OHTSUKA T, FERNANDEZ-DEL CASTILLO C, FURUKAWA T, et al. International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas[J]. Pancreatology, 2024. DOI: 10.1016/j.pan.2023.12.009.[ Online ahead of print]

Relative Articles

[1]	Shuyang ZHANG, Yanzhen BI, Shousheng LIU, Sheng LIU, Yongning XIN. Differentially expressed microRNAs in plasma exosomes from patients with chronic hepatitis B or hepatitis B virus-related acute-on-chronic liver failure: A bioinformatics analysis[J]. Journal of Clinical Hepatology, 2023, 39(8): 1848-1856. doi: 10.3969/j.issn.1001-5256.2023.08.013
[2]	Committee of Minimally Invasive Therapy in Oncology， Chinese Anti-Cancer Association, Committee of Ablation Therapy in Oncology， Chinese Anti-Cancer Association. Chinese expert consensus on Co-Ablation System for the treatment of primary liver cancer （2023 edition）[J]. Journal of Clinical Hepatology, 2023, 39(12): 2793-2797.
[3]	Yao ZHANG, Kai ZHANG, Pengdong KANG, Chao MA. Research advances in microRNA-200c in pancreatic cancer[J]. Journal of Clinical Hepatology, 2022, 38(4): 961-964. doi: 10.3969/j.issn.1001-5256.2022.04.045
[4]	Huijun XIE, Nasot Rashed, Yong NING, Chuan GAO. Current status of research on circulating microRNAs as diagnostic markers for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(2): 448-451. doi: 10.3969/j.issn.1001-5256.2021.02.042
[5]	Sheng CHEN, Guoxiang CHEN, Zhongming HE, Shujie CHENG, Jisen ZHAO. Role of miRNA in the development and progression of cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2021, 37(9): 2241-2245. doi: 10.3969/j.issn.1001-5256.2021.09.048
[6]	Xuemei DING, Shilun WU, Wenbing SUN. Value of preoperative microRNA-192 in peripheral blood mononuclear cells in predicting microvascular invasion of solitary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1121-1125. doi: 10.3969/j.issn.1001-5256.2021.05.028
[7]	Xiuhong HUANG, Xiaoli XIE, Huiqing JIANG. Value of a microRNA risk score model in predicting the prognosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1110-1115. doi: 10.3969/j.issn.1001-5256.2021.05.026
[8]	Wu Jie, Li JingTao, Wei HaiLiang, Yan ShuGuang, Fan Yu, Guo YingJun, Chang ZhanJie. Advances in the role of microRNA in the intervention of malignant transformation of precancerous lesions of the liver by regulating the activation of hepatic stellate cells[J]. Journal of Clinical Hepatology, 2020, 36(7): 1650-1654. doi: 10.3969/j.issn.1001-5256.2020.07.045
[9]	Wu JunYi, Lai ZhiDe, Tian YiFeng, Wang YaoDong. Expression and clinical significance of serum exosomal microRNA-221-3p in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(8): 1768-1772. doi: 10.3969/j.issn.1001-5256.2020.08.018
[10]	Zhang ShiWan, Yu XueQin, Chen Fang, Mei YiHan, Mei XiaoPing. Biological characteristics of exosome microRNA and its role in the development and progression of liver fibrosis[J]. Journal of Clinical Hepatology, 2020, 36(9): 2083-2086. doi: 10.3969/j.issn.1001-5256.2020.09.039
[11]	Cheng YaFei, Wang Bin, Wang ShiMing. Role of microRNAs in gallbladder carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(8): 1900-1904. doi: 10.3969/j.issn.1001-5256.2020.08.049
[12]	Wang ZhiXin, Gou Ping, Yu WenHao, Ren Li, Yang DanCaiRang, Wang HaiJiu, Fan HaiNing. Measurement and bioinformatics analysis of exosomes microRNAs in bile of hepatic alveolar echinococcosis patients with biliary tract invasion[J]. Journal of Clinical Hepatology, 2020, 36(9): 2045-2049. doi: 10.3969/j.issn.1001-5256.2020.09.027
[13]	Huang XiangJun, Zhang WenXing. Expression features and clinical significance of the microRNA-888 gene family in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(1): 119-122. doi: 10.3969/j.issn.1001-5256.2019.01.022
[14]	Niu YaQian, Chang YuLing, Liu Fang, Zhao Chuan, Chen Che. Regulatory role of microRNA in aerobic glycolysis in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(9): 2082-2084. doi: 10.3969/j.issn.1001-5256.2019.09.044
[15]	Zhang YuRui. Correlation between microRNA-520a and clinicopathological features of HBV-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2017, 33(4): 689-693. doi: 10.3969/j.issn.1001-5256.2017.04.018
[16]	Zhang ZhuQing, Lu ShuMing, Wang HuaLi, Xu MengYao, Li ChunYan, Xin Yue, Zhao JunJun. Expression of microRNA-222 in hepatocellular carcinoma tissue and its clinical significance[J]. Journal of Clinical Hepatology, 2017, 33(8): 1502-1505. doi: 10.3969/j.issn.1001-5256.2017.08.018
[17]	Wang DongXu, Huo TingTing, Tian YaoWen, Zhao Lei. Current status of research on microRNA associated with colorectal cancer liver metastasis[J]. Journal of Clinical Hepatology, 2016, 32(12): 2387-2390. doi: 10.3969/j.issn.1001-5256.2016.12.034
[18]	Li Qiang, Zhuo QiBin, Huang YuXian, Chen Liang. Diagnosis and treatment of hepatocellular carcinoma from a new perspective of miRNAs[J]. Journal of Clinical Hepatology, 2015, 31(6): 977-981. doi: 10.3969/j.issn.1001-5256.2015.06.037
[19]	Lin Kun, Ci DanWangJiu, Chang ZhiHui, Liu ZhaoYu. Clinical value of circulating micro RNAs in hepatic,biliary and pancreatic carcinomas[J]. Journal of Clinical Hepatology, 2015, 31(5): 790-795. doi: 10.3969/j.issn.1001-5256.2015.05.040
[20]	Qu YaChao, LYU Jun. Research progress in serum microRNA detection for diagnosis of hepatocellular carcinoma [J]. Journal of Clinical Hepatology, 2014, 30(3): 228-232. doi: 10.3969/j.issn.1001-5256.2014.03.008

Supplements(0)

Cited By

Cited by

Periodical cited type(2)

1.	张玉婷，李嘉泰，宋晓静，丁方回，岳平，闫少林，李俊峰，张立婷，李汛. 不同IgM水平的原发性胆汁性胆管炎患者治疗应答及预后特点分析. 胃肠病学和肝病学杂志. 2025(02): 250-253 .
2.	曹玫华，林欢. 泼尼松联合熊去氧胆酸对原发性胆汁性胆管炎合并自身免疫性肝炎的治疗效果. 深圳中西医结合杂志. 2024(19): 108-111 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (2062) PDF downloads(472)